Published in Eur J Clin Microbiol Infect Dis on March 21, 2012
Cholera and other vibrioses in the United States. N Engl J Med (1985) 5.17
Wound infections caused by Vibrio vulnificus and other marine bacteria. Epidemiol Infect (2005) 1.54
Pathogenesis of infection by clinical and environmental strains of Vibrio vulnificus in iron-dextran-treated mice. Infect Immun (2000) 1.42
Antibiotic efficacy against Vibrio vulnificus in the mouse: superiority of tetracycline. J Pharmacol Exp Ther (1983) 1.42
Vibrio vulnificus infection: diagnosis and treatment. Am Fam Physician (2007) 1.27
In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus. Antimicrob Agents Chemother (2002) 1.07
Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Arch Intern Med (2006) 1.06
Vibrio vulnificus infection: clinical manifestations, pathogenesis, and antimicrobial therapy. J Microbiol Immunol Infect (2003) 1.06
Discrimination of viable Vibrio vulnificus cells from dead cells in real-time PCR. J Microbiol Methods (2005) 1.05
Vibrio vulnificus infections associated with raw oyster consumption--Florida, 1981-1992. MMWR Morb Mortal Wkly Rep (1993) 1.03
In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agents. Antimicrob Agents Chemother (1985) 1.02
Comparison of conventional, nested, and real-time PCR assays for rapid and accurate detection of Vibrio vulnificus. J Clin Microbiol (2008) 1.00
Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother (1989) 1.00
In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus. Eur J Clin Microbiol Infect Dis (2010) 0.94
Development of a quantitative real-time polymerase chain reaction targeted to the toxR for detection of Vibrio vulnificus. J Microbiol Methods (2005) 0.94
In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus. Antimicrob Agents Chemother (2005) 0.94
Oral doxycycline for neuroborreliosis. Lancet Neurol (2008) 0.92
Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus. Transfusion (2009) 0.84
Synergistic antimicrobial effect of cefotaxime and minocycline on proinflammatory cytokine levels in a murine model of Vibrio vulnificus infection. J Microbiol Immunol Infect (2007) 0.77
Discrimination of viable and dead Vibrio vulnificus after refrigerated and frozen storage using EMA, sodium deoxycholate and real-time PCR. J Microbiol Methods (2009) 0.75
Childhood meningiomas associated with meningioangiomatosis: report of five cases and literature review. Neuropathol Appl Neurobiol (2002) 1.65
Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene (2011) 1.39
Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-kappaB and p38 MAPK in HMC-1 human mast cell line. Inflamm Res (2007) 1.15
Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia (2012) 0.95
In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus. Eur J Clin Microbiol Infect Dis (2010) 0.94
Aberrant ventral striatal responses during incentive processing in unmedicated patients with obsessive-compulsive disorder. Acta Psychiatr Scand (2010) 0.92
Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2. Br J Cancer (2003) 0.91
Application of neuronavigation system to brain tumor surgery with clinical experience of 420 cases. Minim Invasive Neurosurg (2006) 0.83
Risk and prognostic factors for acute GVHD based on NIH consensus criteria. Bone Marrow Transplant (2012) 0.81
Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes Metab (2015) 0.79
The shooty callus induced by suppression of tobacco CHRK1 receptor-like kinase is a phenocopy of the tobacco genetic tumor. Plant Cell Rep (2004) 0.76
Predictors of decrease in ankle-brachial index among patients with diabetes mellitus. Diabet Med (2012) 0.76
Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA? Bone Marrow Transplant (2013) 0.76
Decision for salvage treatment after transanal endoscopic microsurgery. Surg Endosc (2007) 0.76
Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib. Herz (2013) 0.75
A small molecule inhibitor of Mitf-E-box DNA binding and its depigmenting effect in melan-a cells. J Eur Acad Dermatol Venereol (2011) 0.75